



(51) International Patent Classification:

C07D 215/20 (2006.01) *A61K 31/47* (2006.01)
C07D 401/12 (2006.01) *A61P 25/00* (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2014/020881

(22) International Filing Date:

5 March 2014 (05.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/785,872 14 March 2013 (14.03.2013) US

(71) Applicant: **DART NEUROSCIENCE, LLC** [US/US];
12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(72) **Inventors:** **BASINGER, Jillian**; 2715 Fairfield St., San Diego, CA 92110 (US). **BREITENBUCHER, James**; 2433 N. Summit Circle Glen, Escondido, CA 92026 (US). **FREESTONE, Graeme**; 8020 Avenida Navidad #43, San Diego, CA 92122 (US). **GUPTA, Varsha**; 241 Village Run East, Encinitas, CA 92024-3045 (US). **KAPLAN, Alan**; 9785 Wren Bluff Dr., San Diego, CA 92127 (US). **MAK, Chi-Ching**; 12057 World Trade Dr. #3, San Diego, CA 92128 (US). **PRATT, Benjamin**; 1057 Guadalajara Dr., Encinitas, CA 92024 (US). **SANTORA, Vincent**; 13325 Via Sabbia, Unit 3, San Diego, CA 92129 (US). **SENGUPTA, Dipanjan**; 9121 Togan Ave., San Diego, CA 92129 (US). **VALDEZ, Lino**; 6838 Briarwood Dr., Carlsbad, CA 92011 (US).

(74) **Agent:** **MILLER, Kimberly, J.**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS

(57) **Abstract:** The invention provides a chemical entity of Formula (I), wherein R¹, R², R³, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive or motor impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

